RHYTHM PHARMACEUTICALS INC's ticker is RYTM and the CUSIP is 76243J105. A total of 173 filers reported holding RHYTHM PHARMACEUTICALS INC in Q4 2023. The put-call ratio across all filers is 0.09 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $602,350 | -10.7% | 14,670 | 0.0% | 0.00% | 0.0% |
| Q4 2023 | $674,380 | +100.5% | 14,670 | 0.0% | 0.00% | 0.0% |
| Q3 2023 | $336,310 | +39.8% | 14,670 | +0.5% | 0.00% | 0.0% |
| Q2 2023 | $240,589 | +49.4% | 14,590 | +4.3% | 0.00% | – |
| Q1 2022 | $161,000 | +15.0% | 13,990 | 0.0% | 0.00% | – |
| Q4 2021 | $140,000 | -22.7% | 13,990 | +1.1% | 0.00% | – |
| Q3 2021 | $181,000 | -33.2% | 13,844 | 0.0% | 0.00% | -100.0% |
| Q2 2021 | $271,000 | +5.4% | 13,844 | +60.2% | 0.00% | 0.0% |
| Q4 2020 | $257,000 | – | 8,641 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 735,000 | $13,112,400 | 3.93% |
| NEA Management Company, LLC | 2,909,956 | $51,913,615 | 3.59% |
| Frazier Life Sciences Management, L.P. | 2,164,739 | $38,618,944 | 2.80% |
| RA Capital Management | 5,516,067 | $98,406,635 | 2.23% |
| Samsara BioCapital, LLC | 345,293 | $6,160,027 | 1.27% |
| Rock Springs Capital Management LP | 1,597,123 | $28,492,674 | 0.68% |
| Baker Brothers Advisors | 6,498,267 | $115,929,083 | 0.63% |
| HighVista Strategies LLC | 35,478 | $632,928 | 0.52% |
| Nan Fung Group Holdings Ltd | 32,520 | $580,157 | 0.40% |
| GREAT POINT PARTNERS LLC | 97,544 | $1,740,185 | 0.34% |